527 related articles for article (PubMed ID: 26377633)
1. Brain endothelial dysfunction in cerebral adrenoleukodystrophy.
Musolino PL; Gong Y; Snyder JM; Jimenez S; Lok J; Lo EH; Moser AB; Grabowski EF; Frosch MP; Eichler FS
Brain; 2015 Nov; 138(Pt 11):3206-20. PubMed ID: 26377633
[TBL] [Abstract][Full Text] [Related]
2. Cerebral adrenoleukodystrophy: a demyelinating disease that leaves the door wide open.
Aubourg P
Brain; 2015 Nov; 138(Pt 11):3133-6. PubMed ID: 26503938
[No Abstract] [Full Text] [Related]
3. Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.
Singh J; Olle B; Suhail H; Felicella MM; Giri S
J Neurochem; 2016 Jul; 138(1):86-100. PubMed ID: 26849413
[TBL] [Abstract][Full Text] [Related]
4. Lack of adrenoleukodystrophy protein enhances oligodendrocyte disturbance and microglia activation in mice with combined Abcd1/Mag deficiency.
Dumser M; Bauer J; Lassmann H; Berger J; Forss-Petter S
Acta Neuropathol; 2007 Dec; 114(6):573-86. PubMed ID: 17828604
[TBL] [Abstract][Full Text] [Related]
5. Modeling and rescue of defective blood-brain barrier function of induced brain microvascular endothelial cells from childhood cerebral adrenoleukodystrophy patients.
Lee CAA; Seo HS; Armien AG; Bates FS; Tolar J; Azarin SM
Fluids Barriers CNS; 2018 Apr; 15(1):9. PubMed ID: 29615068
[TBL] [Abstract][Full Text] [Related]
6. ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.
Baarine M; Beeson C; Singh A; Singh I
J Neurochem; 2015 May; 133(3):380-96. PubMed ID: 25393703
[TBL] [Abstract][Full Text] [Related]
7. HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
Singh J; Khan M; Singh I
J Lipid Res; 2011 Nov; 52(11):2056-69. PubMed ID: 21891797
[TBL] [Abstract][Full Text] [Related]
8. ABCD1 dysfunction alters white matter microvascular perfusion.
Lauer A; Da X; Hansen MB; Boulouis G; Ou Y; Cai X; Liberato Celso Pedrotti A; Kalpathy-Cramer J; Caruso P; Hayden DL; Rost N; Mouridsen K; Eichler FS; Rosen B; Musolino PL
Brain; 2017 Dec; 140(12):3139-3152. PubMed ID: 29136088
[TBL] [Abstract][Full Text] [Related]
9. Evidence of oxidative stress in very long chain fatty acid--treated oligodendrocytes and potentialization of ROS production using RNA interference-directed knockdown of ABCD1 and ACOX1 peroxisomal proteins.
Baarine M; Andréoletti P; Athias A; Nury T; Zarrouk A; Ragot K; Vejux A; Riedinger JM; Kattan Z; Bessede G; Trompier D; Savary S; Cherkaoui-Malki M; Lizard G
Neuroscience; 2012 Jun; 213():1-18. PubMed ID: 22521832
[TBL] [Abstract][Full Text] [Related]
10. ABCD2 is a direct target of β-catenin and TCF-4: implications for X-linked adrenoleukodystrophy therapy.
Park CY; Kim HS; Jang J; Lee H; Lee JS; Yoo JE; Lee DR; Kim DW
PLoS One; 2013; 8(2):e56242. PubMed ID: 23437103
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy.
Weinhofer I; Forss-Petter S; Zigman M; Berger J
Hum Mol Genet; 2002 Oct; 11(22):2701-8. PubMed ID: 12374760
[TBL] [Abstract][Full Text] [Related]
12. Abcd2 is a strong modifier of the metabolic impairments in peritoneal macrophages of ABCD1-deficient mice.
Muneer Z; Wiesinger C; Voigtländer T; Werner HB; Berger J; Forss-Petter S
PLoS One; 2014; 9(9):e108655. PubMed ID: 25255441
[TBL] [Abstract][Full Text] [Related]
13. Astrocytes and mitochondria from adrenoleukodystrophy protein (ABCD1)-deficient mice reveal that the adrenoleukodystrophy-associated very long-chain fatty acids target several cellular energy-dependent functions.
Kruska N; Schönfeld P; Pujol A; Reiser G
Biochim Biophys Acta; 2015 May; 1852(5):925-36. PubMed ID: 25583114
[TBL] [Abstract][Full Text] [Related]
14. Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy.
Singh J; Khan M; Singh I
J Lipid Res; 2009 Jan; 50(1):135-47. PubMed ID: 18723473
[TBL] [Abstract][Full Text] [Related]
15. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes.
Weber FD; Wiesinger C; Forss-Petter S; Regelsberger G; Einwich A; Weber WH; Köhler W; Stockinger H; Berger J
Hum Mol Genet; 2014 May; 23(10):2542-50. PubMed ID: 24363066
[TBL] [Abstract][Full Text] [Related]
16. A novel mutation in the ABCD1 gene of a Moroccan patient with X-linked adrenoleukodystrophy: case report.
Karkar A; Barakat A; Bakhchane A; Fettah H; Slassi I; Dorboz I; Boespflug-Tanguy O; Nadifi S
BMC Neurol; 2015 Nov; 15():244. PubMed ID: 26607867
[TBL] [Abstract][Full Text] [Related]
17. X-linked adrenoleukodystrophy mice demonstrate abnormalities in cholesterol metabolism.
Weinhofer I; Forss-Petter S; Kunze M; Zigman M; Berger J
FEBS Lett; 2005 Oct; 579(25):5512-6. PubMed ID: 16213491
[TBL] [Abstract][Full Text] [Related]
18. X-linked adrenoleukodystrophy in women: a cross-sectional cohort study.
Engelen M; Barbier M; Dijkstra IM; Schür R; de Bie RM; Verhamme C; Dijkgraaf MG; Aubourg PA; Wanders RJ; van Geel BM; de Visser M; Poll-The BT; Kemp S
Brain; 2014 Mar; 137(Pt 3):693-706. PubMed ID: 24480483
[TBL] [Abstract][Full Text] [Related]
19. Cerebral inflammation in X-linked adrenoleukodystrophy.
McGuinness MC; Smith KD
Arch Immunol Ther Exp (Warsz); 1999; 47(5):281-7. PubMed ID: 10604233
[TBL] [Abstract][Full Text] [Related]
20. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects.
Kemp S; Berger J; Aubourg P
Biochim Biophys Acta; 2012 Sep; 1822(9):1465-74. PubMed ID: 22483867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
